Treatment with tolebrutinib led to greater confirmed disability improvement at 6 months compared with placebo in patients ...

No added benefits in slowing MS disability progression were found in a study that increased Ocrevus dosing to 2-3 times the ...

The study aimed to determine whether treatment with high dose ocrelizumab would provide an additional benefit in slowing disability progression.

Scientists have for the first time looked deep into the protein structure that may determine our vision—and discovered that ...